scholarly journals 945 Re-Audit of Incorrect Tcis; Are We Now Listing the Right Teeth

2021 ◽  
Vol 108 (Supplement_2) ◽  
Author(s):  
K Matharu ◽  
A Shah ◽  
M Shorafa
Keyword(s):  
Data Collection ◽  
Tooth Extraction ◽  
Clinical Governance ◽  
Retrospective Data ◽  
Cause Analysis ◽  
Root Cause ◽  
Retrospective Data Collection ◽  
Audit Cycle ◽  
To Come ◽  
The Right

Abstract Introduction In 2018 in our OMFS out-patients department there were two wrong tooth extraction (WTE) events- at a Clinical Governance meeting we identified that TCI (‘to come in’ forms) were being completed incorrectly; from December 2018 to February 2019 there were 6 separate forms where the teeth listed for extraction was different to the teeth that were planned for extraction. As a result, our first stage audit involved data collection and root cause analysis of the incorrectly completed forms. As a result of the findings of the first stage audit, we decided to implement a change to TCI forms. Aim To assess whether TCI forms were being correctly completed following on change to TCI forms. Data collection Retrospective data collection from September 2019- January 2020 analysing any occurrences of incorrect TCI forms Results No further incidents of incorrect TCI forms since September 2019 and WTE since the last occurrence in 2018. Conclusions Although an incorrect TCI form was not listed as a potential cause for the two WTE events that occurred within the department, incorrect documentation is a known risk factor for WTEs. This completed audit cycle demonstrates successful learning from the WTEs and the implementation of beneficial changes.

scholarly journals Tonsillectomy Bleed Rates across the CHEER Practice Research Network

2016 ◽  
Vol 155 (1) ◽  
pp. 28-32 ◽  
Author(s):  
Walter T. Lee ◽  
David L. Witsell ◽  
Kourosh Parham ◽  
Jennifer J. Shin ◽  
Nikita Chapurin ◽  
...  
Keyword(s):  
Data Collection ◽  
Postoperative Bleeding ◽  
Age Groups ◽  
Postoperative Hemorrhage ◽  
Research Network ◽  
Practice Research ◽  
Retrospective Data ◽  
Significant Difference ◽  
Retrospective Data Collection ◽  
A Site

Objectives (1) Compare postoperative bleeding in the CHEER network (Creating Healthcare Excellence through Education and Research) among age groups, diagnoses, and practice types. (2) Report the incidence of bleeding by individual CHEER practice site based on practice guidelines. Study Design Retrospective data collection database review of the CHEER network based on ICD-9 and CPT codes related to tonsillectomy patients. Setting Multisite practice–based network. Subjects and Methods A total of 8347 subjects underwent tonsillectomy as determined by procedure code within the retrospective data collection database, and 107 had postoperative hemorrhage. These subjects had demographic information and related diagnoses based on the CPT and ICD-9 codes collected. Postoperative ICD-9 and CPT codes were used to identify patients who also had postoperative bleed. Variables included age (<12 vs ≥12 years), diagnoses (infectious vs noninfectious), and practice type (community vs academic). Statistical analysis included multivariate logistic regression variables predictive of postoperative bleeding, with P < .05 considered significant. Results Thirteen sites contributed data to the study (7 academic, 6 community). There was postoperative bleeding for an overall bleed rate of 1.3%. Patients ≥12 years old had a significantly increased bleed rate when compared with the younger group (odds ratio, 5.98; 95% confidence interval: 3.79-9.44; P < .0001). There was no significant difference in bleed rates when practices or diagnoses were compared. Conclusion A site descriptor database built to expedite clinical research can be used for practice assessment and quality improvement. These data were also useful to identify patient risk factors for posttonsillectomy bleed.

The Criminology of Wrongful Conviction

2016 ◽  
Vol 33 (1) ◽  
pp. 82-106 ◽  
Author(s):  
Richard A. Leo
Keyword(s):  
Criminal Justice ◽  
Justice System ◽  
Wrongful Conviction ◽  
Wrongful Convictions ◽  
Cause Analysis ◽  
Academic Field ◽  
Root Cause ◽  
Improve Accuracy ◽  
Current Article ◽  
To Come

This article reflects on the author’s 2005 article, “Rethinking the Study of Miscarriages of Justice,” which sought to describe what scholars empirically knew at that time about the phenomenon, causes, and consequences of wrongful convictions in America. The 2005 article argued that the study of wrongful convictions constituted a coherent academic field of study and set forth a vision for a more sophisticated, insightful, and generalizable criminology of wrongful conviction. In this current article, the author revisits the ideas first developed in “Rethinking the Study of Miscarriages of Justice” to evaluate what scholars have learned about wrongful convictions in the last decade, and what challenges lie ahead for developing a more robust criminology of wrongful conviction. The article concludes that there have been significant theoretical, methodological, and substantive advances in the last decade, but that a root cause analysis of wrongful convictions has yet to come to fruition and urges empirical scholars to begin to study other sources of error and inaccuracy in the criminal justice system. Scholars should develop a criminology of erroneous outcomes, not just of erroneous conviction. By studying both sets of outcomes, scholars can improve accuracy and reduce errors across the board.

Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection

Vaccine ◽  
2020 ◽  
Vol 38 (9) ◽  
pp. 2198-2201 ◽  
Author(s):  
Yosef Uziel ◽  
Veronica Moshe ◽  
Beata Onozo ◽  
Andrea Kulcsár ◽  
Diána Tróbert-Sipos ◽  
...  
Keyword(s):  
Data Collection ◽  
Immunosuppressive Therapy ◽  
Rheumatic Diseases ◽  
Retrospective Data ◽  
Retrospective Data Collection

scholarly journals PIN4 CONSUMPTION OF ANTIBIOTICS IN EUROPE: RESULTS OF THE ESAC RETROSPECTIVE DATA COLLECTION

2003 ◽  
Vol 6 (6) ◽  
pp. 746
Author(s):  
M Ferech ◽  
M Elseviers ◽  
R Vander Stichele ◽  
H Goossens
Keyword(s):  
Data Collection ◽  
Retrospective Data ◽  
Retrospective Data Collection

Therapy of Acquired Aplastic Anemia (AA) with Rabbit Antithymocyte Globulin (rATG): A Retrospective Analysis by the Working Group on Non-Malignant Disorders of Hematopoiesis of the German Society of Hematology and Oncology (DGHO),

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3434-3434
Author(s):  
Britta Höchsmann ◽  
Christiane Neher ◽  
Ulrich Germing ◽  
Janne Vehreschild ◽  
Juliane Eggermann ◽  
...  
Keyword(s):  
Data Collection ◽  
Aplastic Anemia ◽  
Research Funding ◽  
Response Rate ◽  
Retrospective Data ◽  
First Line ◽  
Off Label ◽  
Best Response ◽  
Retrospective Data Collection

Abstract Abstract 3434 Introduction: Several clinical trials established treatment with horse ATG (hATG) and cyclosporine A (CsA) as standard treatment of AA in patients (pts) who are not candidates for stem cell transplantation (SCT). In 2007 the hATG brand Lymphoglobulin® was withdrawn from the market. As the hATG brand ATGAM®, is not approved in Europe, hATG was replaced by rabbit ATG (rATG). Recently a large prospective randomized one-center study from NIH, USA comparing hATG ATGAM®/CsA and rATG Thymoglobulin®/CsA in untreated AA showed significantly lower response rates and survival with rATG. To obtain further information on rATG treatment in an unselected AA population, especially with a higher median of age and use of different rATG dosages we performed a retrospective data collection of first line rATG therapy on several centers. This shall reflect outcome after rATG in a real-world situation. Methods: Retrospective data collection and analysis of first line rATG treatment of AA after approval by Ethical Committee. Results: Up to now retrospective data of 64 pts from 18 centres in Germany were analysed. Characteristics of the pts: 30 male, 34 female; median age at time of therapy 54 years (6–80 years); 87.5% of pts had idiopathic AA. 51.6% of pts had severe AA, 32.8% very severe AA and 15.6% non-severe AA. Median granulocyte count was 0.3 G/l. 86% of the pts required red blood cell and 92% platelet transfusions. 56 of the evaluable pts received Thymoglobulin® and 5 pts Fresenius ATG S®. 52 of the 56 Thymoglobulin®-treated pts got this therapy in the years 2007–2011, i.e. not as deliberate primary choice of rATG but because hATG was no longer available. Median daily dose of Thymoglobulin® was 3.5 mg/kg (range from 2.5 – 3.75 mg/kg) for 5 days. 62 of 64 pts received additional immunosuppressive therapy with CsA and 19 of 64 pts received G-CSF. The median follow-up for surviving pts was 558.5 days (range, 78–3800 days). Response rates at time of best response of pts were CR in 10/58 pts (17%), PR in 18/58 pts (31%) and NR in 30/58 pts (52%) (only surviving patients with a minimum follow-up of 120 days were analyzed). Median interval to best response was 217 days. Response rate (PR+CR) was 16/33 (48.5%) in pts who received a Thymoglobulin® dose of > 3.5 –3.75 mg/kg/day versus only 4/14 (28.6%) group of 14 pts with a dose of > 2.5 to < 3.5 mg/kg/day (p=0.17; Fisher`s exact test). Relapses occurred in 3/28 responders and clonal evolution was observed in 3 pts (2 PNH, 1 MDS). Eighteen of 63 evaluable pts received allogenic SCT after ATG-therapy and were censored at the date of SCT. 23% of 44 pts without SCT died. In 6 of these 10 pts death was caused by infections. Other causes of death were bleeding, cardiac event, acute respiratory distress syndrome, adynamia. Overall probability of survival at 3 years was 75.8% (95% confidence interval (CI): 61.8 – 89.9%) and survival censored for SCT was 79.9% (CI: 66.0–92.8%). Survival was significantly better in responders (PR and CR) (94.1% at 3 years; CI: 82.9–100%) than in non-responders (58.0% at 3 years; CI 34.0 – 81.3%) (p=0.04; log-rank test). Adverse events were reported in 79.4% of 63 evaluable pts consisting of anaphylaxis/allergy in 27.3%, serum sickness in 12.7%, fever/chills in 34.5%, and bacterial/viral/fungal infections in 54.5% of pts. Conclusion: Response rate and survival after rATG+CsA in this retrospective analysis is lower than in historical controls (e.g. hATG+CsA treatment in previous controlled studies of the German AA Study Group and the EBMT AA Working Party; Frickhofen et al., Blood 2003; Tichelli et al., Blood 2011) and rate of (early) infections seem to be high. Our results are in accordance with recent reports from other groups. Additionally the results of this retrospective data analysis suggest a benefit for the patient group treated with a Thymoglobulin® dosage of > 3.5 –3.75 mg/kg/day compared to lower doses (< 3.5 mg/kg/day). There is growing evidence that best results in terms of response and survival are obtained by hATG-based immunosuppression. hATG can not be replaced by rATG without negative impact on patient outcome. There is need for action to achieve availability of hATG worldwide. If hATG is not available, treatment with rATG should be considered instead of no treatment or treatment with CsA alone since still about half of the patients respond to rATG. Disclosures: Höchsmann: Alexion: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Amgen: Consultancy; Genzyme: Consultancy, Honoraria, Research Funding. Off Label Use: The use of the horse ATG ATGAM in Aplastic Anemia is off-label in Europe. At the moment no horse ATG with approval is available in Europe. Schrezenmeier:Genzyme: Consultancy, Honoraria, Research Funding; Alexion: Consultancy, Honoraria; Novartis: Consultancy, Research Funding.

Sign in / Sign up

Export Citation Format

Share Document